Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis

被引：1

作者：

Lio, Peter ^{[1
,2
]}

Kim, Yestle ^{[3
,4
]}

Balu, Sanjeev ^{[4
]}

Costantino, Halley ^{[5
]}

Bates, Dawn ^{[5
]}

Rene, Cassandra ^{[5
]}

Lopez, Amanda ^{[6
]}

Soung, Jennifer ^{[7
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[2] Med Dermatol Associates Chicago, Chicago, IL USA

[3] Madrigal Pharmaceut, W Conshohocken, PA USA

[4] LEO Pharma, Madison, NJ USA

[5] Cerner Enviza, Kansas City, MO USA

[6] Patient Living Atop Dermatitis, Rahway, NJ USA

[7] Harbor UCLA Med Ctr, Torrance, CA USA

来源：

关键词：

moderate-to-severe; patient-reported outcomes; real-world; tralokinumab;

D O I：

10.1093/bjd/ljad498.052

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

553

引用

页码：II50 / II51

页数：2